Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2018 07:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Company reported positive Phase 3 data in patients with post-surgical pain following bunionectomy Initiation of second pivotal Phase 3 trial expected in the second half of 2018 NEW YORK, Aug. 14,...
June 19, 2018 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
June 06, 2018 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain

NEW YORK, June 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
May 21, 2018 06:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain

IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference...
May 03, 2018 07:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
March 28, 2018 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
March 05, 2018 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics to Present at March Investor Conferences

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
March 01, 2018 07:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
February 06, 2018 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
January 02, 2018 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain

NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...